Trials / Completed
CompletedNCT00161785
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 340 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 67 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess: * TBE antibody persistence 2 and 3 years after the third TBE vaccination with FSME-IMMUN 0.5ml by means of ELISA and neutralization test (NT). * TBE antibody response to a booster vaccination with FSME-IMMUN 0.5ml, by means of ELISA and NT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | FSME-IMMUN 0.5ml |
Timeline
- Start date
- 2004-06-01
- Completion
- 2005-07-01
- First posted
- 2005-09-13
- Last updated
- 2015-05-21
Locations
2 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT00161785. Inclusion in this directory is not an endorsement.